[go: up one dir, main page]

MX2019008993A - Compuestos moduladores del receptor de hidrocarburos de arilo (ahr). - Google Patents

Compuestos moduladores del receptor de hidrocarburos de arilo (ahr).

Info

Publication number
MX2019008993A
MX2019008993A MX2019008993A MX2019008993A MX2019008993A MX 2019008993 A MX2019008993 A MX 2019008993A MX 2019008993 A MX2019008993 A MX 2019008993A MX 2019008993 A MX2019008993 A MX 2019008993A MX 2019008993 A MX2019008993 A MX 2019008993A
Authority
MX
Mexico
Prior art keywords
ahr
aryl hydrocarbon
hydrocarbon receptor
modulator compounds
compounds
Prior art date
Application number
MX2019008993A
Other languages
English (en)
Inventor
Steeneck Christoph
Hoffmann Thomas
Deuschle Ulrich
Albers Michael
Original Assignee
Phenex Pharmaceuticals Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phenex Pharmaceuticals Ag filed Critical Phenex Pharmaceuticals Ag
Publication of MX2019008993A publication Critical patent/MX2019008993A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a compuestos que pueden actuar como moduladores del receptor de hidrocarburos de arilo (AhR) y, en particular, como antagonistas de AhR. La invención además se refiere al uso de los compuestos para el tratamiento y/o profilaxis de enfermedades y/o condiciones a través de la unión de dicho receptor de hidrocarburos de arilo por dichos compuestos.
MX2019008993A 2017-02-01 2018-02-01 Compuestos moduladores del receptor de hidrocarburos de arilo (ahr). MX2019008993A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17000157 2017-02-01
PCT/EP2018/052538 WO2018141855A1 (en) 2017-02-01 2018-02-01 Aryl hydrocarbon receptor (ahr) modulator compounds

Publications (1)

Publication Number Publication Date
MX2019008993A true MX2019008993A (es) 2019-12-19

Family

ID=57960222

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019008993A MX2019008993A (es) 2017-02-01 2018-02-01 Compuestos moduladores del receptor de hidrocarburos de arilo (ahr).

Country Status (25)

Country Link
US (1) US11376241B2 (es)
EP (1) EP3577115B1 (es)
JP (1) JP2020505467A (es)
KR (1) KR20190113902A (es)
CN (1) CN110234650A (es)
AR (1) AR110790A1 (es)
AU (1) AU2018216955B2 (es)
BR (1) BR112019015704A2 (es)
CA (1) CA3051034A1 (es)
CL (1) CL2019002112A1 (es)
CO (1) CO2019007882A2 (es)
CR (1) CR20190393A (es)
CU (1) CU20190067A7 (es)
EA (1) EA201991600A1 (es)
EC (1) ECSP19055179A (es)
IL (1) IL268082A (es)
MX (1) MX2019008993A (es)
NI (1) NI201900075A (es)
PE (1) PE20191479A1 (es)
PH (1) PH12019550136A1 (es)
SG (1) SG11201906959RA (es)
TW (1) TWI674260B (es)
UA (1) UA122746C2 (es)
UY (1) UY37590A (es)
WO (1) WO2018141855A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI752155B (zh) 2017-02-01 2022-01-11 德商菲尼克斯製藥股份有限公司 芳香烴受體(AhR)調節劑化合物
TWI674260B (zh) 2017-02-01 2019-10-11 德商菲尼克斯製藥股份有限公司 芳基烴受體(AhR)調節劑化合物
EP4219495A1 (en) 2018-02-06 2023-08-02 Ideaya Biosciences, Inc. Ahr modulators
WO2020021024A1 (en) * 2018-07-26 2020-01-30 Phenex Pharmaceuticals Ag Substituted bicyclic compounds as modulators of the aryl hydrocarbon receptor (ahr)
CN109813913B (zh) * 2019-01-31 2021-11-09 中国医学科学院肿瘤医院 芳烃受体(AhR)在预测免疫治疗效果中的应用
EP4003337A4 (en) 2019-07-30 2023-06-28 Oregon State University Aryl hydrocarbon receptor activators
KR102351515B1 (ko) * 2019-12-17 2022-01-14 (주)수파드엘릭사 아릴 탄화수소 수용체의 활성을 억제하는 폡타이드 및 이를 이용하는 화장료 조성물
WO2021148628A1 (en) * 2020-01-23 2021-07-29 Phenex Pharmaceuticals Ag Oxalamide substituted heterocyclic compounds as modulators of the aryl hydrocarbon receptor (ahr)
CN114181212B (zh) * 2020-09-15 2023-06-06 山东轩竹医药科技有限公司 哒嗪酮类AhR抑制剂
KR20230127271A (ko) * 2020-12-28 2023-08-31 셀진 코포레이션 헤테로시클릭 화합물 및 기생충성 질환을 위한 그의용도
CN115572282B (zh) * 2021-07-05 2024-07-09 华东理工大学 含芳杂环结构的吡唑酰胺类化合物及其制备方法和应用
WO2024081428A2 (en) * 2022-10-14 2024-04-18 Oregon State University Selective modulators of ahr-regulated transcription and method for using such modulators to treat cancer

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8225991A (en) 1990-07-31 1992-03-02 Teikoku Hormone Mfg. Co., Ltd. 2-phenylindole derivative
DK0948495T3 (da) 1996-11-19 2004-06-01 Amgen Inc Aryl- og heteroarylsubstitueret, kondenseret pyrrol som antiinflammatoriske midler
AU2003270426A1 (en) 2002-09-12 2004-04-30 Avanir Pharmaceuticals PHENYL-INDOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION
US20050032869A1 (en) 2003-07-08 2005-02-10 Pharmacia Italia S.P.A. Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
EP1966199B1 (en) 2005-11-18 2010-10-20 F. Hoffmann-La Roche AG Azaindole-2-carboxamide derivatives
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
WO2011046954A1 (en) 2009-10-13 2011-04-21 Ligand Pharmaceuticals Inc. Hematopoietic growth factor mimetic small molecule compounds and their uses
ES2791684T3 (es) * 2009-11-02 2020-11-05 Ariagen Inc ITE para la intervención y erradicación del cáncer
US20130338201A1 (en) * 2009-11-02 2013-12-19 Ahr Pharmaceuticals, Inc. Method of Cancer Treatment with 2-(1H-Indole-3-Carbonyl)-Thiazole-4-Carboxylic Acid Methyl Ester
PT2531501E (pt) * 2010-02-03 2014-02-17 Takeda Pharmaceutical Inibidores da cinase de regulação do sinal de apoptose 1
US8410117B2 (en) 2010-03-26 2013-04-02 Hoffmann-La Roche Inc. Imidazopyrimidine derivatives
TWI619713B (zh) 2010-04-21 2018-04-01 普雷辛肯公司 用於激酶調節的化合物和方法及其適應症
BR112013002079B1 (pt) 2010-07-27 2021-09-14 Trustees Of Boston University Modificadores do receptor de aril hidrocarboneto (ahr) como novos terapêuticos contra o câncer
GB201104267D0 (en) * 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
HK1207379A1 (en) 2012-10-17 2016-01-29 霍夫曼-拉罗奇有限公司 6-aminoindole derivatives as trp channel antagonists
BR112015014752B1 (pt) 2012-12-21 2022-07-05 Plexxikon, Inc Compostos e seus uso para modulação de cinase
TWI752155B (zh) * 2017-02-01 2022-01-11 德商菲尼克斯製藥股份有限公司 芳香烴受體(AhR)調節劑化合物
TWI674260B (zh) 2017-02-01 2019-10-11 德商菲尼克斯製藥股份有限公司 芳基烴受體(AhR)調節劑化合物
TW201835070A (zh) 2017-02-21 2018-10-01 德商菲尼克斯製藥股份有限公司 芳香烴受體(AhR)調節劑化合物

Also Published As

Publication number Publication date
AR110790A1 (es) 2019-05-02
ECSP19055179A (es) 2019-08-30
PE20191479A1 (es) 2019-10-16
CL2019002112A1 (es) 2019-12-20
UA122746C2 (uk) 2020-12-28
EP3577115B1 (en) 2020-12-02
US11376241B2 (en) 2022-07-05
UY37590A (es) 2018-02-28
US20210260045A1 (en) 2021-08-26
CO2019007882A2 (es) 2019-10-09
TWI674260B (zh) 2019-10-11
TW201838991A (zh) 2018-11-01
CR20190393A (es) 2019-10-21
NI201900075A (es) 2019-10-30
EP3577115A1 (en) 2019-12-11
SG11201906959RA (en) 2019-08-27
JP2020505467A (ja) 2020-02-20
EA201991600A1 (ru) 2020-03-10
CU20190067A7 (es) 2020-03-04
KR20190113902A (ko) 2019-10-08
BR112019015704A2 (pt) 2020-04-07
AU2018216955B2 (en) 2020-09-17
AU2018216955A1 (en) 2019-08-01
WO2018141855A1 (en) 2018-08-09
CA3051034A1 (en) 2018-08-09
CN110234650A (zh) 2019-09-13
PH12019550136A1 (en) 2020-03-02
IL268082A (en) 2019-09-26

Similar Documents

Publication Publication Date Title
PH12019550155A1 (en) ARYL HYDROCARBON RECEPTOR (AhR) MODULATOR COMPOUNDS
PH12019550135A1 (en) Aryl hydrocarbon receptor (ahr) modulator compounds
PH12019550136A1 (en) ARYL HYDROCARBON RECEPTOR (AhR)MODULATOR COMPOUNDS
SA521422031B1 (ar) مركبات 2 – فورميل – 3 – هيدروكسي فينيلوكسي ميثيل قادرة على تعديل الهيموجلوبين
NZ737399A (en) Ccr2 modulators
MY200943A (en) Modulators Of The Integrated Stress Pathway
EP4406957A3 (en) Aryl receptor modulators and methods of making and using the same
EA201891251A1 (ru) Бициклические ингибиторы pad4
PH12016501192A1 (en) Tetrahydropyridopyrazines modulators of gpr6
MX2016004540A (es) Tiazolopirimidinonas como moduladores de la actividad de receptores de n-metil-d-aspartato (nmda).
PH12016501393A1 (en) Substituted bicyclic heteroaryl compounds as rxr agonists
PH12017501601A1 (en) Use of isolated fractions of mastic gum for treating optic neuropathy
PH12017500910A1 (en) Use of sigma receptor ligands in osteoarthritis
UA118312C2 (uk) 3,5-діамінопіразолові інгібітори кінази
NZ765691A (en) Aryl receptor modulators and methods of making and using the same